Dalbavancin in clinical practice: a particular place for the elderly?

Autor: Wackenheim C; Infectious Diseases Department, CH Alpes Léman, Contamine-sur-Arve, France. c.wackenheim@miit-lyon.com., Le Maréchal M; Infectious Diseases Department, CHU de Grenoble Alpes, Grenoble, France. mlemarechal@chu-grenoble.fr.; Groupe de Recherche en Infectiologie Clinique (GRIC), CIC, CHU Grenoble Alpes, Grenoble, France. mlemarechal@chu-grenoble.fr., Pluchart H; Pharmacy Department, CHU de Grenoble Alpes, Grenoble, France. hpluchart@chu-grenoble.fr., Gavazzi G; Groupe de Recherche en Infectiologie Clinique (GRIC), CIC, CHU Grenoble Alpes, Grenoble, France. ggavazzi@chu-grenoble.fr.; Geriatric Medicine Department, CHU de Grenoble Alpes, Grenoble, France. ggavazzi@chu-grenoble.fr., Blanc M; Infectious Diseases Department, CHU de Grenoble Alpes, Grenoble, France. myriam.blanc@chu-grenoble.fr., Caspar Y; Groupe de Recherche en Infectiologie Clinique (GRIC), CIC, CHU Grenoble Alpes, Grenoble, France. ycaspar@chu-grenoble.fr.; Bacteriology Laboratory, Institute of Biology and Pathology, CHU de Grenoble Alpes, Grenoble, France. ycaspar@chu-grenoble.fr., Pavese P; Infectious Diseases Department, CHU de Grenoble Alpes, Grenoble, France. ppavese@chu-grenoble.fr.; Groupe de Recherche en Infectiologie Clinique (GRIC), CIC, CHU Grenoble Alpes, Grenoble, France. ppavese@chu-grenoble.fr.
Jazyk: angličtina
Zdroj: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2022 Jun; Vol. 41 (6), pp. 977-979. Date of Electronic Publication: 2022 Apr 26.
DOI: 10.1007/s10096-022-04427-2
Abstrakt: We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin's administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: